Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01323062 · ClinicalTrials.gov registry record · Phase 1

Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

A Phase 1 study of Non-small Cell Lung Cancer (NSCLC), sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target
2
Study locations

NCT01323062 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 26 participants, below the 288-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01323062, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC), has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target
2
Study locations

Study Summary

This is a non-randomized, open-label Phase 1b trial to establish the safety and recommended phase 2 dose (RP2D) of bavituximab in combination with pemetrexed and carboplatin in subjects with previously untreated stage IV non-squamous non-small cell lung cancer (NSCLC).

Conditions Studied

Non-small Cell Lung Cancer (NSCLC)

Interventions

  • DRUG Bavituximab

Study Locations (2)

North Carolina

  • Lineberger Comprehensive Cancer Center, UNC - Chapel Hill

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2011-05
Est. Completion 2018-10-01
Phase Phase 1

Sponsor

UNC Lineberger Comprehensive Cancer Center

366 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01323062

The ClinicalTrials.gov registry entry for NCT01323062 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (91% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which Bavituximab is the first listed.

NCT01323062 reports 2 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01323062 about?

NCT01323062 is a clinical study titled "Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects". This is a non-randomized, open-label Phase 1b trial to establish the safety and recommended phase 2 dose (RP2D) of bavituximab in combination with pemetrexed and carboplatin in subjects with previously untreated stage IV non-squamous non-small cell lung cancer (NSCLC).

What is the current status of trial NCT01323062?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2011-05. Estimated completion is 2018-10-01.

What conditions does trial NCT01323062 study?

This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).

What interventions are being tested in trial NCT01323062?

The interventions under investigation include: Bavituximab (DRUG).

Who is sponsoring clinical trial NCT01323062?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01323062 being conducted?

This trial has 2 study locations across North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-small Cell Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-small Cell Lung Cancer (NSCLC)

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.